Fierce Pharma, February 20, 2015 | By Emily Wasserman Bayer has won an approval from England’s National Institute for Health and Care Excellence (NICE) for its popular eye drug Eylea. But it was a mixed result. The drugmaker offered a discount to get the approval and then NICE granted it for some, but not all, […]
All posts by: Anke
[cvg-video videoId=’10’ width=’865′ height=’500′ mode=’playlist’/]
HIKMA filling the gaps when bigger operators have plant problems and drug shortages arise FiercePharma Manufacturing, 13. March 2014 By Eric Palmer Middle East-based Hikma Pharmaceuticals is not a large pharma player. The drugmaker’s $1.365 billion in 2013 revenues is about what a Big Pharma company would report for sales of one drug. But it […]
Sun Pharma (India) plant was banned by the FDA for manufacturing issues March 13, 2014 | By Eric Palmer in FiercePharma A Sun Pharma plant has joined the growing ranks of Indian operations banned by the FDA for manufacturing issues. Unlike Ranbaxy Laboratories and Wockhardt, two other Indian generics players that have recently felt the […]
FiercePharma, December 11, 2013 | By Tracy Staton Gilead Sciences ($GILD) can take the sort of pricing protest that greeted its breakthrough hepatitis C treatment Sovaldi this week–the kind from access-to-medicine advocates. But when payers balk, that’s a different story. A horror story, even, that could frighten drugmakers long accustomed to pricing freedom in the […]
FiercePharma, December 16, 2013 | By Tracy Staton More new drugs. More drug sales? Not so much. As The Wall Street Journal reports, pharma companies racked up 271 new drug approvals from 2006 to 2010, but only a baker’s dozen of them have broken through the blockbuster barrier. That’s a major comedown from the previous […]
[cvg-video videoId=’8′ width=’865′ height=’500′ mode=’playlist’/]
Pharmatimes Online. 15 May 2013 The pharmaceutical industry has now entered the Outcomes Era where compounds must supply convincing evidence of a new drug’s value, with proof of the best possible health outcomes and additional benefits if it is to achieve attractive price and reimbursement levels, says new research.As many as 60% of pharmaceutical executives […]